van Eer Kahren, Middeldorp Marit, Dzebisasjvili Tsira, Lamkaraf Najima, de Melker Hester E, Steenbergen Renske D M, King Audrey J
National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, The Netherlands.
Pathology, Amsterdam University Medical Center location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
J Infect Dis. 2023 Oct 18;228(8):1012-1022. doi: 10.1093/infdis/jiad080.
Human papillomavirus (HPV) viral load (VL) is associated with persistence, which increases cervical cancer risk. The bivalent vaccine protects against oncogenic HPV-16/18 and cross-protects against several nonvaccine types. We examined the effect of 2-dose (2D) and 3-dose (3D) vaccination on HPV prevalence and VL in clearing infections and persistent infections, 6 years and 12 years postvaccination, respectively.
Vaginal swabs collected from the "HPV Amongst Vaccinated and Non-vaccinated Adolescents" study (HAVANA, 3D-eligible) and HAVANA-2 (2D-eligble) participants were genotyped for HPV with the SPF10-DEIA-LiPA25 system. HPV VL was measured with type-specific quantitative polymerase chain reaction (qPCR).
HPV-16, -18, -31, -33, and -45 clearing and/or persistent infection prevalence and HPV-16, -18, and -31 VLs in clearing infections were significantly reduced in 3D-vaccinated women compared to unvaccinated women. Except for HPV-11 and -59 clearing infections, no significant VL differences were observed among vaccinated women, ≤6 and >6 years post-vaccination. Infection numbers were low in 2D-eligible women, with no HPV-16/18 in vaccinated women. No VL differences for the remaining types were found.
3D vaccination reduces HPV prevalence in clearing infections and persistent infections and decreases HPV VLs in clearing infections, 12 years post-vaccination for vaccine and several nonvaccine types. 2D-eligible women had low infection numbers, with no HPV-16/18 among vaccinated women.
人乳头瘤病毒（HPV）病毒载量（VL）与持续性感染相关，而持续性感染会增加宫颈癌风险。二价疫苗可预防致癌性HPV-16/18，并对几种非疫苗型别具有交叉保护作用。我们分别研究了2剂（2D）和3剂（3D）疫苗接种在接种后6年和12年对HPV清除率和病毒载量在清除感染和持续性感染方面的影响。
从“接种和未接种疫苗青少年中的HPV”研究（哈瓦那，符合3剂接种条件）和哈瓦那-2（符合2剂接种条件）的参与者中收集阴道拭子，使用SPF10-DEIA-LiPA25系统对HPV进行基因分型。采用型特异性定量聚合酶链反应（qPCR）测量HPV病毒载量。
与未接种疫苗的女性相比，接种3剂疫苗的女性中HPV-16、-18、-31、-33和-45的清除和/或持续性感染率以及清除感染中的HPV-16、-18和-31病毒载量显著降低。除HPV-11和-59清除感染外，接种疫苗的女性在接种后≤6年和>6年之间未观察到显著的病毒载量差异。符合2剂接种条件的女性感染数量较少，接种疫苗的女性中没有HPV-16/18。其余型别的病毒载量未发现差异。
接种3剂疫苗可降低清除感染和持续性感染中的HPV流行率，并降低清除感染中的HPV病毒载量，在接种疫苗后12年对疫苗型别和几种非疫苗型别均有效。符合2剂接种条件的女性感染数量较少，接种疫苗的女性中没有HPV-16/18。
